Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||51%|
|1 Day Vol Adjusted Return||-2.0|
|1 Month Vol Adjusted Return||-5.7|
|3 Month Vol Adjusted Return||2.7|
|6 Month Vol Adjusted Return||4.8|
|20 Days SMA Price ZScore||-2.4|
|50 Days SMA Price ZScore||-0.4|
|12 -26 Days PPO||-0.8|
|1 Month Average Short Volume Ratio||33.1|
|1 Day Volume Change ZScore||2.3|
|1 Month Daily Vol||7.1|
Betsy Price, Fort Worth Mayor, joins Yahoo Finance’s Kristin Myers to discuss Texas lifting its mask mandates and reopening businesses.
The U.S. Food and Drug Administration has granted Emergency Use Authorization to the vaccines of Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and Johnson & Johnson (NYSE: JNJ). In this Motley Fool Live video recorded on Feb. 26, 2021, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss the next two candidates nearing the U.S. finish line -- a pharmaceutical company and a biotech company. Corinne Cardina: Let's talk about the companies that may be n...
Less than a year before the COVID-19 started its relentless march across the globe Novavax (NASDAQ: NVAX) was facing delisting from the Nasdaq. The 33-year-old Maryland-based pharmaceutical company didn't have a single approved shot after hundreds of millions of dollars invested in its R&D efforts. Wall Street likes to take bets on unproven biotech such as Moderna Inc (NASDAQ: MRNA), but it can be unforgiving of failure. But now, Novavax is now on the verge of getting approval in the UK, which w...
Novavax (NASDAQ: NVAX) reported a widening loss in the most recent quarter. Of course, both of these points have to do with the company's investigational coronavirus vaccine. Novavax may be next to cross the vaccine-race finish line.
Dr. Heather Yeo, SurvivorNet Medical Advisor & Associate Professor of Surgery and Associate Professor of Population Health Sciences at New York Presbyterian Weill Cornell Medicine, joins Yahoo Finance’s Kristin Myers to discuss the latest coronavirus updates.
Poland-based biotech firm Mabion has signed a preliminary agreement to manufacture Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine, reports Bloomberg. The polish company will get 40 million zlotys ($11 million) in loans and equity from a state-run fund to support doubling its production capacity in Poland. Mabion will start commercial-scale production trials of Novavax shot. European Union countries such as Poland have struggled to secure supplies of COVID-19 vaccines sourced by Brussels, leading ...
Novavax said in January its coronavirus vaccine was 89.3% effective in a Phase 3 test. It's also effective against variants. It's now seeking authorization. Is NVAX stock a buy?
A vaccine shortage is on track to turn into a vaccine bounty in just a few months. The story of the Covid-19 vaccine rollout in the U.S., over the two and a half months since the first shots went into the first arms, has been one of scarcity. President said late Tuesday that there will be enough vaccine doses for every adult in the U.S. by the end of May. And by late spring or early summer, there could be an oversupply, according to a note out Tuesday by Jefferies analyst Michael Yee.
Novavax (NASDAQ: NVAX) has completed enrollment in its late-stage study of COVID-19 vaccine NVX-CoV2373 that's being conducted in the U.S. and Mexico. In this Motley Fool Live video recorded on Feb. 24, 2021, Fool.com contributors Keith Speights and Brian Orelli discuss whether or not there are any yellow flags with Novavax's COVID-19 vaccine trial so far. Keith Speights: We have a question about Novavax's vaccine technology.